A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody.
Wu, N.C., Yuan, M., Bangaru, S., Huang, D., Zhu, X., Lee, C.D., Turner, H.L., Peng, L., Yang, L., Burton, D.R., Nemazee, D., Ward, A.B., Wilson, I.A.(2020) PLoS Pathog 16: e1009089-e1009089
- PubMed: 33275640 
- DOI: 10.1371/journal.ppat.1009089
- Primary Citation of Related Structures:  
7JN5 - PubMed Abstract: 
Epitopes that are conserved among SARS-like coronaviruses are attractive targets for design of cross-reactive vaccines and therapeutics. CR3022 is a SARS-CoV neutralizing antibody to a highly conserved epitope on the receptor binding domain (RBD) on the spike protein that is able to cross-react with SARS-CoV-2, but with lower affinity ...